OTOGL
Otogelin-like protein
Also known as: C12orf64, FLJ90579, OTOGL_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q3ZCN5
- Gene
- OTOGL
- Ensembl
- ENSG00000165899
- Chromosome
- 12
- Canonical length
- 2353 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Cytosol
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
The protein encoded by this gene belongs to the otogelin family. This gene is expressed in the inner ear of vertebrates with the highest level of expression seen at the embryonic stage and lowest in adult. Knockdown studies in zebrafish suggest that this gene is essential for normal inner ear function. Mutations in this gene are associated with autosomal recessive deafness. [provided by RefSeq, Dec 2012]
Canonical amino-acid sequenceUniProt
2353 residues, UniProt reviewed canonical sequence.
>Q3ZCN5|OTOGL
1 MNIVRKLNLM IPWSIFLLHV LLFSLQEYIC ASSILMGTSK NGFNENRQKR ALLAAQFEAT
61 SPRYFFHDAI NWGESKIKGS CPYECLNGAF CSKTGTCDCQ IFQALGTRCQ IIPNMGNGRD
121 GICKTWGQYH FETFDGIYYY FPGNCSYIFA KDCGDLEPRY TVWVHNSPKC LGSVYSCYRS
181 ISLFFSNQEE IRIYGHEIKK NGISLTLPQT IGQIFIEKLA DYILVKTTFG FSLAWDGISG
241 IYLKLSEDHK GKSCGLCGNY NDIQSDDFII LQEDYTEDIA MFANSWSVQT PDDTKCVLTP
301 SDFPNPCSSG MPAFEAIFFK CQILLQFPFL SCHEYIDPYL YIASCVNDLC KTDDDETYCR
361 AATEYARACS HAGYPIQDWR DDFPACTDKC DDSFVHRDCI SCCPPTCTFE KQCLGSNLHC
421 LDGCYCPDGL VMDNGTCISL ENCPCGFHGL AYSVGSKIEQ ECTECVCVGG VWNCTEQDCP
481 VQCSVVGDSH FTTFDGRHYS FIGMCQYILV KGTGKDKFTI TLQKAPCEQN LGLVCLQSIT
541 LILEDDFNKQ VTLGRGGQIL TSPNQGFNLN GIVEIQTLSS LFILLKTTFG LKILFAIDGE
601 RIYIQLTSAW KRRTLGLCGT FNGNIRDDFL SPSGMIEGTP QLHANAWRVS STCFAPVHVP
661 VVDPCNINQQ NIGYAAHCDV IHQELFAPCH IYISPGLYYQ LCRHDACKCG SSCLCNALAH
721 YAYLCGQHGV PIDFRTQISF CAVVCQKGML YHHCSSFCLH SCISLSSPEQ CSDDCAEGCN
781 CPEGKFYEDT LNFCVPIFHC RCHYRGSVYQ PGELIPTPSG LCQCSNGTVK CDELATPSAV
841 HICPEGKEYF DCRFPDPELP AGGVNCETTC ANLAMNFTCT PSSPCISGCV CAPGMAEHRG
901 KCYVPESCPC IWKDWEYLSG EVIATPCYTC VCRRGMFNCT YYPCPAVCTI YGDRHYYSFD
961 GLEYDYISDC QVFLIKSADD SDISVIAQNK KCFDNDIVCS KSVLISVGDT EIYLNDTPYK
1021 QKQSGFFLEN KSTYQLWKAG YYIVVYFPEK DITILWDRKT TIHIKVGPQW KNKLSGLCGN
1081 FDKCTSNDMT TSNNLEVRNA RVFGDSWALG QCESPDETIK PCEAHQNKFP YAKKECSILY
1141 SDIFASCRNV IDVTSFAKNC HEDTCNCNLG GDCECLCTSI AAYAYKCCQE GISIHWRSST
1201 VCSLDCEYYN EGLGEGPYML ASYGQSGLVL GANMTSRSVF CLPRSSVHTS LFFYFMITPG
1261 LFKEKVSSLA LVSLESAERP NYFLYVHDND TLSLELWEAN SAFHRRATFF HHQGLWIPGY
1321 SAFELYSKKG FFIIFTDSSV KASKYDDSEE FKHSSSFSIE EIQAAVPYRK MCEWRYEPCA
1381 TPCFKTCSDP EALACKFLPP VEGCLPYCPK NMILDEVTLK CVYPRDCIPV IPTEPTLMPP
1441 AKPTVPMFTV WEMITPSDIT VFDMLTPTTG LECEPQKFDP VYDCSQYICL NMEWQLYNWS
1501 LNCPKDVEMP DCGFRGRPVQ VNSDICCPEW ECPCRCSMLS ELSIITFDGN NAALYSMASY
1561 ILVRIPGEII VAHIEKCSMN QNGNSLKKLA PSGRISGLCF KKLNVTTPIH KIIVNRLARK
1621 VEVDSIVVPL PFSSQELSIE DSGSMYVITT PAGLIIKWSH LTGIIDIHFG FRFNLSSYTE
1681 GLCGICNEDP DDDLRMQNGT IITNMEDIGL FIESWEIEKS FEVTMRRPVR NCTEHDCSQC
1741 IDLLNRRIFI PCHDKVSPED FCEKMWINYT YFWNYECDAL SAYVALCNKF DICIQWRTPD
1801 YCSLSCPEGK EYQPCVRPCE ARTCLNQWFY GHTSCLNLRE DCVCKVGTIL HRPHSAQCIP
1861 EKECACTDSE DQPRTAGEIW NGGIDECTLY KCLENGSIIP IEPDCDEEPT PVCEREAEVV
1921 MGIIDKWTCC SKEVCGCDTT LCETSIPTCT NSQKLIVGHS PLSCCPQYKC ECDPLKCPSI
1981 STPECREDQF MIQVRQEEPC CFSPFCVCES CTKPVPLCHD GEFLTVDLNS THFCCPQYYC
2041 VCEPNLCPMP LLNCAEDMNL VKENVSGQCC PTWHCECNCE NLIMPTCEVG EFTAIDHNFQ
2101 SDCGCIQYLC EKDDVCVFQE VSVLNPGQSM IKYLEEDFCY AIECLEEKDN HTGFHTLNFT
2161 LVNCSKKCDV HQVYTPSPSD YGCCGTCKNV SCKFHMENGT SVVYAVGSTW HYNCTTYECV
2221 KTDEGAIILN YTMVCPPFNE TECKMNEGIV KLYNEGCCKI CKREERICQK VIIKSVIRKQ
2281 DCMSQSPINV ASCDGKCPSA TIYNINIESH LRFCKCCREN GVRNLSVPLY CSGNGTEIMY
2341 TLQEPIDCTC QWNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against OTOGL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 4.8 nTPM
Expression across tissuesHPA
Tissue
- kidney: 4.8 nTPM
- heart muscle: 4.1 nTPM
- colon: 1.5 nTPM
- pituitary gland: 0.8 nTPM
- cerebral cortex: 0.7 nTPM
- placenta: 0.5 nTPM
Single-cell type
- medullary thymic epithelial cells: 197 nCPM
- myonuclei: 83 nCPM
- schwann cells: 71 nCPM
- proximal tubule cells: 65 nCPM
- oligodendrocyte progenitor cells: 60 nCPM
- epididymal efferent duct absorptive cells: 52 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 4.4 nTPM
- basal ganglia: 3 nTPM
- white matter: 1.9 nTPM
- pons: 1.8 nTPM
- midbrain: 1.4 nTPM
- amygdala: 1.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about OTOGL.
Disease | AllUniProt
Conditions OTOGL is implicated in, by any mechanism.
- Deafness, autosomal recessive, 84B (DFNB84B) MIM:614944
Disease | GeneticClinVar
106 pathogenic / likely-pathogenic of 1,246 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Autosomal recessive nonsyndromic hearing loss 84B
- Rare genetic deafness
- OTOGL-related disorder
- Inborn genetic diseases
- Monogenic hearing loss
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.9
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.58
OntologyGO
Biological processes
- inner ear receptor cell stereocilium organization
- intracellular protein localization
- L-arabinose metabolic process
- vibrational conductance of sound to the inner ear
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- VWFC domain
- von Willebrand factor, type D domain
- Trypsin Inhibitor-like, cysteine rich domain
- Cystine knot, C-terminal
- Alpha-L-arabinofuranosidase B, arabinose-binding domain
- VWF/SSPO/Zonadhesin-like, cysteine-rich domain
- Serine protease inhibitor-like superfamily
- Alpha-L-arabinofuranosidase B, arabinose-binding domain superfamily
- Mucin/von Willebrand/Thrombospondin superfamily
- Otogelin-like/Mucin, TIL domain
- Otogelin-like, N-terminal domain
- Otogelin-like, Fn1-VW hybrid domain
- von Willebrand factor type D domain
- Trypsin Inhibitor like cysteine rich domain
- Alpha-L-arabinofuranosidase B (ABFB) domain
- C8 domain
- Otogelin-like Fn1-VW hybrid domain
- Otogelin-like N-terminal
- Otogelin-like/Mucin TIL domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads OTOGL as an antibody target. Whether an autoantibody or antibody against OTOGL could matter depends on whether native OTOGL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
OTOGL is annotated as secreted, so native OTOGL circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label OTOGL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...